BioCentury
ARTICLE | Financial News

Inivata raises £40M series B to support launch of NSCLC liquid biopsy

March 28, 2019 9:14 PM UTC

Inivata completed a £40 million ($52.8 million) series B round to advance the U.S. commercial rollout of its non-small cell lung cancer liquid biopsy following a positive coverage decision from Medicare contractor Palmetto GBA earlier this month.

Inivata Ltd. (Cambridge, U.K.) said the coverage determination paves the way for its InVisionFirst-Lung test to be used in routine care to stratify NSCLC patients...

BCIQ Company Profiles

Inivata Ltd.